Cited by 123Circadian rhythm and melatoninCancer Risks and FactorsCancer, Stress, Anesthesia, and Immune Response

Urinary Melatonin Levels and Postmenopausal Breast Cancer Risk in the Nurses' Health Study Cohort

Open access
Schernhammer, Eva S., Hankinson, Susan E.·2009·Cancer Epidemiology, Biomarkers & Prevention

Abstract

Background: Melatonin seems to play a role in breast cancer etiology, but data addressing the association between melatonin levels and breast cancer risk in postmenopausal women is sparse. Methods: We conducted a nested case-control study in the Nurses' Health Study cohort. First spot morning urine was collected from 18,643 cancer-free women from March 2000 through December 2002. The concentration of the major metabolite of melatonin, 6-sulfatoxymelatonin (aMT6s), was available for 357 postmenopausal women who developed incident breast cancer through May 31, 2006, along with 533 matched control subjects. We used multivariable conditional logistic regression models to investigate associations. All statistical tests were two sided. Results: An increased concentration of urinary aMT6s was statistically significantly associated with a lower risk of breast cancer (odds ratio for the highest versus lowest quartile of morning urinary aMT6s, 0.62; 95% confidence interval, 0.41-0.95; Ptrend = 0.004). There was no apparent modification of risk by hormone receptor status of breast tumors, age, body mass index, or smoking status. Conclusion: Results from this prospective study add substantially to the growing literature that supports an inverse association between melatonin levels and breast cancer risk. (Cancer Epidemiol Biomarkers Prev 2009;18(1):74–9)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-08-0637

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Results from prospective cohort studies consistently suggest that women with the lowest concentration of the main melatonin metabolite sulfatoxymelatonin have the highest risk for breast cancer.

    “Further, results from prospective cohort studies consistently suggest that women with the lowest concentration of the main melatonin metabolite sulfatoxymelatonin, have the highest risk for breast cancer 96, 97.”

    From The inner clock-Blue light sets the human rhythm (2019) · cites this paper as [97]

    The Discussion says the three earlier prospective studies “produced inconsistent results”: two found an inverse association, but one found no association. This paper’s own postmenopausal cohort found an inverse association, but it does not support the claim that prospective studies consistently found the highest risk in women with the lowest levels. (LLM, conf=0.87)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 48 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [17]Travis RC Allen DS Fentiman IS Key TJ Melatonin and breast cancer: a prospective study J Nat Cancer Inst 96 475 482 2004 15026473

Cited by

Sorted by citations

Authors
Schernhammer, E. S., & Hankinson, S. E.
Affiliations
Brigham and Women's Hospital (US)
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2009-01-01
Volume
18
Issue
1
Pages
74-79
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W1979445574
Cited by
123
References
48
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 4 · 2019: 8 · 2018: 5 · 2017: 8 · 2016: 11 · 2015: 6 · 2014: 17 · 2013: 16 · 2012: 10
FWCI
3.59
Type
journal article
Language
en
Open access
Locations
  • Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Emory University
  • National Institutes of Health (5r01ca049449-18)
  • National Cancer Institute (CA-49449, CA-87969, U01CA067262, P01CA087969, R01‐CA049449, CA/ES62984, U01CA049449, R01CA067262)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
  • Health Sciences › Medicine › Psychiatry and Mental health › Cancer, Stress, Anesthesia, and Immune Response
Keywords
melatonin, urinary 6-sulfatoxymelatonin, postmenopausal breast cancer, breast cancer risk, hormone receptor status, Nurses' Health Study
MeSH terms
Adult, Breast Neoplasms, Female, Humans, Melatonin, Middle Aged, Prospective Studies, Surveys and Questionnaires, Risk, Risk Factors, Biomarkers, Tumor, United States, Logistic Models, Case-Control Studies, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review